Skip to content

Efficacy and Mechanism of Wrist-Ankle Acupuncture Nursing Analgesia Mode Based on the "Twelve Cutaneous Regions Theory" for Herpes Zoster Neuralgia

Efficacy and Mechanism of Wrist-Ankle Acupuncture Nursing Analgesia Mode Based on the "Twelve Cutaneous Regions Theory" for Herpes Zoster Neuralgia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002083
Enrollment
Unknown
Registered
2025-10-28
Start date
2024-02-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes Zoster Pain

Interventions

Control Group (Sham WAA + Basic Treatment):Sham Wrist-ankle acupuncture + Basic Treatment
Experimental Group (WAA + Basic Treatment):Wrist-ankle acupuncture + Basic Treatment

Sponsors

The Third Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients with HZ-related pain presenting at the study site between February 1, 2024, and December 30, 2025; 2.Aged 18–80 years, any gender; 3.Numeric Rating Scale (NRS) pain score = 4; 4.Persistent neuralgia following 7 days of antiviral therapy, with pain duration not exceeding 1 month; 5.Cooperate to complete the treatment and adhere to the medication regimen as prescribed. 6.No analgesic use within 3 days prior to enrollment; 7.Willing and able to adhere to the treatment protocol; Capable of understanding study procedures and providing informed consent

Exclusion criteria

Exclusion criteria: (1) Patients with critical conditions (hemodynamic instability, respiratory failure, or respiratory depression requiring intubation); (2) Patients with atypical herpes zoster (such as disseminated herpes zoster, or skin lesions involving the head, face, neck, shoulders, or lower back); (3) Patients with abnormal coagulation function; (4) Patients with cardiovascular and cerebrovascular diseases, kidney, liver, or other organ diseases, or those with mental disorders; (5) Patients with hematologic diseases or poorly controlled blood glucose; (6) Women who are pregnant or breastfeeding; (7) Patients allergic to the treatment drugs; (8) Patients with significant cognitive impairment affecting their understanding of or compliance with the study protocol.

Design outcomes

Primary

MeasureTime frame
Numerical Rating Scale;

Secondary

MeasureTime frame
The State Anxiety Inventory (S-AI);IL-6, IL-8, and TNF-a;The frequency of analgesic use and the occurrence of adverse reactions during the treatment process.;the incidence of Postherpetic neuralgia;

Countries

China

Contacts

Public ContactQun Fang

The Third Affiliated Hospital of Zhejiang Chinese Medical University

644436445@qq.com18958077821

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026